18 completed, 7 terminated, 1 recruiting, 1 withdrawn. 11 Phase 1, 11 Phase 3, 6 Phase 2.
By phase and status
Follow latrepirdine: new trials by email Literature Review of latrepirdine trials Research Report on latrepirdine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
DMB-I (INN: Latrepirdine), Memantine Hydrochloride 20 MG, Placebo - Alzheimer Type Dementia | Phase 3 | Recruiting | Bigespas LTD | 450 | 2025-11-20 | 2025-12-10 |
DMB-I in the Treatment of Alzheimer Type Dementia
DMB-I (Dimebon), Placebo - Alzheimer Disease, Dementia of Alzheimer Type | Phase 2 | Completed | Bigespas LTD | 133 | 2023-12-27 | 2025-03-28 |
An Extension of the CONCERT Protocol (DIM18)
Dimebon - Alzheimer's Disease | Phase 3 | Terminated | Medivation, Inc. | 672 | 2010-04-01 | 2016-09-27 |
A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
PF-01913539 5 mg, Placebo - Alzheimer's Disease, Dementia | Phase 2 | Withdrawn | Pfizer | | 2010-04-01 | 2010-06-29 |
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
Dimebon tablet for oral administration - Alzheimer's Disease | Phase 3 | Terminated | Pfizer | 5 | 2010-04-01 | 2012-10-02 |
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
Dimebon (latrepirdine) - Huntington Disease | Phase 3 | Terminated | Medivation, Inc. | 362 | 2010-02-01 | 2016-10-12 |
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
Dimebon (latrepirdine), Placebo - Moderate to Severe Alzheimer | Phase 3 | Terminated | Medivation, Inc. | 89 | 2009-10-01 | 2016-09-27 |
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
dimebon, placebo, alprazolam - Alzheimer's Disease, Huntington's Disease | Phase 1 | Completed | Pfizer | 36 | 2009-10-01 | 2013-04-02 |
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
Dimebon - Alzheimer's Disease | Phase 3 | Terminated | Pfizer | 649 | 2009-09-01 | 2012-11-14 |
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
Dimebon 20 mg po TID, Placebo po TID - Alzheimer Disease | Phase 3 | Terminated | Pfizer | 86 | 2009-09-01 | 2012-10-02 |
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole - Alzheimer's Disease, Huntington's Disease | Phase 1 | Completed | Pfizer | 24 | 2009-07-01 | 2009-11-18 |
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Dimebon, Placebo - Huntington Disease | Phase 3 | Completed | Medivation, Inc. | 403 | 2009-07-01 | 2016-10-12 |
A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults
Dimebon - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2009-06-01 | 2009-07-22 |
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Dimebon, Placebo comparator - Alzheimer's Disease | Phase 3 | Completed | Medivation, Inc. | 1003 | 2009-03-01 | 2016-09-27 |
Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
Dimebon - Hepatic Failure | Phase 1 | Completed | Pfizer | 23 | 2009-02-01 | 2009-09-16 |
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
Dimebon - Alzheimer's Disease, Huntington's Disease | Phase 1 | Completed | Pfizer | 20 | 2009-02-01 | 2009-12-30 |
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Warfarin, Dimebon - Alzheimer's Disease, Huntington's Disease | Phase 1 | Completed | Pfizer | 14 | 2009-02-01 | 2018-10-16 |
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Dimebon, Placebo - Alzheimer's Disease | Phase 3 | Completed | Pfizer | 742 | 2009-02-01 | 2018-12-06 |
Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
digoxin, dimebon - Alzheimer Disease, Huntington Disease | Phase 1 | Completed | Pfizer | 12 | 2009-02-01 | 2009-06-12 |
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
Dimebon - Alzheimer's Disease, Huntington's Disease | Phase 1 | Completed | Pfizer | 45 | 2009-02-01 | 2011-04-26 |
Showing 20 of 27. Sign in to see all of them.
Conditions studied
Alzheimer Disease (20) · Huntington Disease (11) · Dementia (4) · Memory Disorders (3) · Neurodegenerative Diseases (3) · Central Nervous System Diseases (1) · Cognitive Dysfunction (1) · Delirium (1) · Liver Failure (1) · Mental Disorders (1) · Nervous System Diseases (1) · Renal Insufficiency (1)
Sponsors
Pfizer (14) · Medivation, Inc. (11) · Bigespas LTD (2)
Countries
United States (18) · Canada (4) · Germany (3) · Russia (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Puerto Rico (2) · Sweden (2) · Chile (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1) · Italy (1)
Top investigators
Karl D Kieburtz, MD (1) · Karl Kieburtz, MD, MPH (1) · Lynn Seely, MD (1)
Results publications
PMID 18640457, PMID 20142523, PMID 23108692, PMID 42141012